Latest FULC reports update at 2024-05-13: 2024-Q1 ∙ 2023-Q4 ∙ 2023-Q1

Fulcrum Therapeutics FULC

$ 6.1 -3.33%

Fulcrum Therapeutics Balance Sheet 2011-2024 | FULC

Annual Balance Sheet Fulcrum Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-14.7 M	-21.7 M	-	-	-	-72.8 M	-407 K	-	-	-	-	-	-
Long Term Debt	8.63 M	10.8 M	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	2.19 M	2.6 M	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	5.54 M	233 K	-	-	-	-	-	-
Total Current Liabilities	13.7 M	16.7 M	19.2 M	26.7 M	12.1 M	-	-	-	-	-	-	-	-
Total Liabilities	22.5 M	27.7 M	23.5 M	34.4 M	23.3 M	9.77 M	3.02 M	-	-	-	-	-	-
Deferred Revenue	-	934 K	4.71 M	14.9 M	3.99 M	-	-	-	-	-	-	-	-
Retained Earnings	-510 M	-412 M	-302 M	-222 M	-151 M	-68.1 M	-35.5 M	-	-	-	-	-	-
Total Assets	258 M	227 M	235 M	130 M	110 M	85.8 M	4.34 M	-	-	-	-	-	-
Cash and Cash Equivalents	25.6 M	35.1 M	35.4 M	57.1 M	96.7 M	-	-	-	-	-	-	-	-
Book Value	235 M	199 M	212 M	95.2 M	87.2 M	76 M	1.32 M	-	-	-	-	-	-
Total Shareholders Equity	235 M	199 M	212 M	95.2 M	87.2 M	-63.7 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Fulcrum Therapeutics

	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	8.1 M	8.63 M	9.14 M	9.65 M	10.1 M	10.8 M	11.5 M	12.2 M	12.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	19 M	22.5 M	23.4 M	24.9 M	24.9 M	27.7 M	26.4 M	34.5 M	31.1 M	23.5 M	24.9 M	27 M	28.7 M	34.4 M	34.4 M	34.4 M	34.4 M	23.3 M	23.3 M	23.3 M	23.3 M	9.77 M	9.77 M	9.77 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	334 K	513 K	737 K	934 K	1.39 M	1.78 M	2.92 M	4.71 M	6.13 M	9.9 M	12.1 M	14.9 M	14.9 M	14.9 M	14.9 M	3.99 M	-	3.99 M	3.99 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-537 M	-510 M	-485 M	-461 M	-437 M	-412 M	-386 M	-362 M	-328 M	-302 M	-279 M	-258 M	-239 M	-222 M	-222 M	-222 M	-222 M	-151 M	-151 M	-151 M	-151 M	-68.1 M	-68.1 M	-68.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	233 M	258 M	279 M	300 M	321 M	227 M	248 M	195 M	220 M	235 M	256 M	138 M	156 M	130 M	130 M	130 M	130 M	110 M	110 M	110 M	110 M	85.8 M	85.8 M	85.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	39.9 M	25.6 M	30.1 M	34 M	34.7 M	35.1 M	90.9 M	40.2 M	33.3 M	35.4 M	65.5 M	56.8 M	101 M	57.1 M	57.1 M	57.1 M	57.1 M	96.7 M	96.7 M	96.7 M	96.7 M	72.8 M	72.8 M	72.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	214 M	235 M	255 M	275 M	296 M	199 M	221 M	161 M	189 M	212 M	231 M	111 M	128 M	95.2 M	95.2 M	95.2 M	95.2 M	87.2 M	87.2 M	87.2 M	87.2 M	76 M	76 M	76 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	214 M	235 M	255 M	275 M	296 M	199 M	221 M	161 M	189 M	212 M	231 M	111 M	128 M	95.2 M	95.2 M	95.2 M	95.2 M	87.2 M	87.2 M	87.2 M	87.2 M	-63.7 M	-63.7 M	-63.7 M	-39.8 M	-33.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency